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ABSTRACT Opsonophagocytic assays are used to measure functional antibodies im-
portant in protection against pneumococcal capsular antigens. There have been ef-
forts to standardize these methods, as the assays are commonly used to measure
vaccine immunogenicity. We report here the results from three international labora-
tories using their own methods, based on the recommended WHO standard method.
We tested 30 pediatric sera, before and after administration of a 13-valent conjugate
pneumococcal vaccine, against all 13 serotypes. The three laboratories demonstrated
good agreement using their own standardized multiplex opsonophagocytosis assay
protocols, particularly postimmunization for those serotypes in the vaccine. While
serotype-speciﬁc IgG methods have already been internationally standardized and
are currently used as a measure of vaccine immunogenicity, this report demon-
strates that despite minor differences in methods and a minor variation in response
to nonvaccine serotypes, the results from opsonophagocytic assays across the three
laboratories may be compared with conﬁdence.
IMPORTANCE When measuring a functional antibody response to pneumococcal
immunization, it is imperative that a speciﬁc, reproducible, accurate, and standard-
ized assay with acceptable inter- and intra-assay variation be advocated internation-
ally to allow for meaningful comparison of results between laboratories. We report
here the results of a collaboration between 3 international laboratories testing 30
pediatric samples against the 13 serotypes in Prevenar13.
KEYWORDS immunization, MOPA, pneumococcal IgG
Pneumonia remains a leading cause of infant mortality in children under 5 years ofage, with almost 1.3 million deaths in 2011 (1). One vaccine-preventable cause
of severe pneumonia, Streptococcus pneumoniae (pneumococcus), causes at least 18%
of severe episodes and 33% of deaths worldwide, with the majority of episodes
occurring in the low- and middle-income countries (2). Data from December 2015
show that pneumococcal immunization programs have been introduced into 129
countries, with global coverage estimated at 37% (3). The majority of pneumococcal
vaccine trials report serotype-speciﬁc IgG as a primary measure of vaccine immu-
nogenicity (4); however, measurement of antibody function provides more relevant
information in terms of host protection.
Antibody-mediated killing of S. pneumoniae by phagocytes, known as opsonophago-
cytosis, is an important mechanism of host protection against pneumococcal infections.
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Opsonophagocytic assays (OPAs) have been developed to evaluate pneumococcal
vaccine immunogenicity by mimicking in vivo opsonophagocytosis.
Guidelines for the measurement of functional serotype-speciﬁc pneumococcal an-
tibodies are detailed in the World Health Organization document Protocol for Multi-
plexed Opsonophagocytic Killing Assay (UAB-MOPA) for Antibodies against Streptococcus
pneumoniae (5). However, laboratories use a variety of methods, often with minor
modiﬁcations, which may result in varied results. It is therefore imperative that a
speciﬁc, reproducible, accurate, and standardized assay with acceptable inter- and
intra-assay variation be advocated internationally to allow for meaningful comparison
of results between laboratories.
We report here a bridging exercise undertaken in 2014 and 2015 between three
international pneumococcal research laboratories. For the purposes of this report, the
laboratories have been deidentiﬁed. Each laboratory used its own standardized MOPA
protocols and reagents to test the common pediatric serum sample panel. This is the
ﬁrst multilaboratory study comparing MOPAs with pediatric samples.
RESULTS
OPAs. Laboratories A and B provided results for all samples. Laboratory C was
unable to report the results for one sample for serotype 1, nine samples for serotype 3,
two samples for serotype 6A, one sample for serotype 18C, and three samples for
serotype 19A due to the samples not passing their laboratory assay criteria of a maximum
killing percentage of 40% or 70% (refer to Table S1 in the supplemental material). A
negative titer (8) was recorded as 4 and was included in all statistical analyses. The
geometric mean opsonic index (GMOI) and 95% conﬁdence intervals (CI) of results
submitted by each laboratory are detailed in Table 1. Refer to Tables S2 to S4 for the
GMOI and 95% CI for sample 1, sample 2, and sample 3.
Scatterplots and Lin’s CCCs. Figure 1 displays representative scatterplots of the
OIs for sample 1, sample 2, and sample 3 when each laboratory’s results are plotted
against the other. For the two serotypes in Prevnar (a 7-valent pneumococcal conjugate
vaccine [PCV7]), serotypes 4 and 18C, agreement was good, and in general, the points
cluster around the diagonal line of agreement. Lin’s concordance correlation coefﬁcient
(CCC) supports this agreement; for serotype 4, in lab A and lab B, the CCC was 0.80, in
lab A and lab C, the CCC was 0.80, in lab B and lab C, the CCC was 0.88 (also for serotype
18C), in lab A and lab C, the CCC was 0.95, in lab A and lab B, the CCC was 0.89, and
in lab B and lab C, the CCC was 0.94 (Table 2).
For the two non-PCV7 serotypes, 3 and 7F, there was greater discordance. For
serotype 3, 53% of samples tested by lab A were below the limit of detection, while this
percentage was 19% or 20% for lab C or lab B, respectively. In the lab A paired
scatterplots for serotype 3, this is clearly seen with the majority of matched titers from
both lab B and lab C above the diagonal line of agreement. For a serotype 3 comparison
TABLE 1 GMOI and 95% CI of OIs from labs A, B, and C for study samples
Vaccine(s) Serotype
Lab A GMOI (95% CI);
no. of samples
Lab B GMOI (95% CI);
no. of samples
Lab C GMOI (95% CI);
no. of samples
PCV7 4 375 (148–949); 30 1,144 (408–3,206); 30 908 (374–2,204); 30
6B 1,434 (578–3,558); 30 10,798 (4,664–24,996); 30 4,134 (1,841– 9,285); 30
9V 862 (446–1,663); 30 15,262 (7,226–32,234); 30 1,890 (1,083–3,300); 30
14 522 (191–1,425); 30 11,100 (6,680–18,445); 30 3,158 (1,923–5,184); 30
18C 417 (162–1,077); 30 937 (308–2,849); 30 411 (142–1,195); 29
19F 664 (321–1,372); 30 4,719 (2,146–10,376); 30 1,603 (852–3,017); 30
23F 397 (189–838); 30 4,024 (2,114–7,659); 30 1,456 (729–2,911); 30
23vPPV and PCV13 1 8 (4–15); 30 27 (10–73); 30 9 (4–18); 29
3 13 (7–22); 30 76 (34–168); 30 54 (25–117); 21
5 16 (8–35); 30 43 (17–107); 30 17 (7–38); 30
6A 103 (30–352); 30 1,794 (496–6,494); 30 864 (237–3,144); 28
7F 196 (55–698); 30 14,441 (8,696–23,981); 30 2,634 (1,183–5,867); 30
19A 64 (27–153); 30 670 (245–1,832); 30 353 (134–931); 27
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FIG 1 Opsonic index for lab A versus lab B, lab A versus lab C, and lab B versus lab C for serotypes 4, 18C, 3, and 7F, with triangles
representing sample 1, open circles representing sample 2, and black circles representing sample 3.
MOPA Comparison following Pneumococcal Immunization
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between lab B and lab C, Lin’s concordance data support a good concordance of 0.86;
however, the scatterplot demonstrates that the OIs reported by lab B were higher
overall. This was also seen for serotype 7F, with lab A reporting a negative titer for 33%
(10 of 30) of samples and lab C reporting a negative titer for 7% (2 of 30) of samples.
Lab B reported a positive titer for all 30 samples. Scatterplots for the remaining
serotypes are shown in Fig. S1 to S3.
Overall, Lin’s concordance coefﬁcients indicate a moderate-to-high agreement be-
tween lab A and lab C. The concordance between lab A and lab C for pooled OI results
was 0.79 (95% CI, 0.75 to 0.83), while serotype-speciﬁc coefﬁcients ranged between 0.42
(serotype 7F) and 0.98 (serotype 1). The agreement was serotype dependent, with
highest agreement for serotypes 1, 5, and 18C and lowest agreement for serotypes 7F
and 14.
The concordance between lab A and lab B for all serotypes combined was 0.65 (95%
CI, 0.60 to 0.69), while serotype-speciﬁc coefﬁcients ranged between 0.21 (serotype 7F)
and 0.89 (serotype 18C). The agreement was also serotype dependent, with highest
agreement for serotypes 4, 5, and 18C and lowest agreement for serotypes 7F and 9V.
The concordance between lab B and lab C for all serotypes combined was 0.88 (95%
CI, 0.86 to 0.90), while serotype-speciﬁc coefﬁcients ranged between 0.48 (serotype 7F)
and 0.94 (serotype 18C). The agreement was serotype dependent, with highest agree-
ment for serotypes 6A, 18C, and 4 and lowest agreement for serotypes 7F and 9V.
Figures S1 to S3 demonstrate scatterplots between the three laboratories, which
show good agreement for most serotypes after injection of the 13-valent pneumococ-
cal conjugate vaccine (PCV13), with the points clustering around the diagonal line.
However, for serotypes 7F and 14, the agreement was weak, as shown by Lin’s
concordance coefﬁcients (for serotype 7F, the lab A and lab C CCC was 0.42, for lab A
and lab B, the CCC was 0.21, and for lab B and lab C, the CCC was 0.48; for serotype 14,
the lab A and lab C CCC was 0.45, the lab A and lab B CCC was 0.29, and the lab B and
lab C CCC was 0.60) (Tables 3 to 5).
Opsonic index and serotype-speciﬁc IgG. At the time of sample 1, all children
were aged 18 months and had received 2 or 3 infant doses of PCV7. The samples were
taken 1 month after a reduced (20%) dose of 23-valent Pneumovax (23vPPV). The
serotype-speciﬁc IgG geometric mean concentration (GMC) for all PCV7 serotypes was
greater than 2.06 g/ml, and the three laboratories reported a positive titer (OI 8) for
all 7 serotypes. The serotype-speciﬁc IgG GMC and corresponding OI for the non-PCV7
serotypes were substantially lower (Table S2).
TABLE 2 Lin’s CCCs with 95% CI for pairwise comparisons and ICCs with 95% CIa
Vaccine(s) Serotype
Lin’s concordance coefﬁcient (95% CI) [no. of pairwise comparisons]
Intraclass correlation
coefﬁcient (95% CI)
[no. of pairwise
comparisons]Lab A and lab B Lab A and lab C Lab B and lab C
PCV7 4 0.80 (0.64, 0.89) 0.80 (0.64, 0.90) 0.88 (0.77, 0.94) 0.87 (0.78, 0.93)
6B 0.64 (0.46, 0.77) 0.83 (0.71, 0.91) 0.86 (0.76, 0.92) 0.92 (0.85, 0.95)
9V 0.28 (0.11, 0.43) 0.67 (0.45, 0.81) 0.49 (0.31, 0.63) 0.73 (0.57, 0.84)
14 0.29 (0.15, 0.42) 0.45 (0.27, 0.60) 0.60 (0.42, 0.74) 0.65 (0.47, 0.80)
18C 0.89 (0.80, 0.94) 0.95 (0.90, 0.97) [29] 0.94 (0.88, 0.96) [29] 0.95 (0.92, 0.98) [29]
19F 0.61 (0.44, 0.74) 0.78 (0.63, 0.88) 0.82 (0.71, 0.89) 0.91 (0.84, 0.95)
23F 0.36 (0.16, 0.53) 0.66 (0.46, 0.80) 0.72 (0.54, 0.84) 0.77 (0.63, 0.87)
23vPPV and PCV13 1 0.63 (0.44, 0.77) 0.98 (0.96, 0.99) [29] 0.69 (0.50, 0.82) [29] 0.79 (0.66, 0.88) [29]
3 0.43 (0.21, 0.60) 0.57 (0.28, 0.76) [21] 0.86 (0.75, 0.93) [21] 0.73 (0.57, 0.85) [21]
5 0.79 (0.64, 0.89) 0.96 (0.93, 0.98) 0.83 (0.69, 0.91) 0.90 (0.83, 0.95)
6A 0.55 (0.33, 0.71) 0.65 (0.42, 0.80) [28] 0.92 (0.85, 0.96) [28] 0.83 (0.71, 0.90) [28]
7F 0.21 (0.10, 0.31) 0.42 (0.21, 0.59) 0.48 (0.29, 0.64) 0.58 (0.39, 0.75)
19A 0.58 (0.39, 0.72) 0.69 (0.49, 0.83) [27] 0.88 (0.77, 0.93) [27] 0.88 (0.79, 0.93) [27]
aLab A and lab B supplied results for all serotypes for the 30 samples. Lab C was unable to provide results for one sample for serotype 1, nine samples for serotype 3,
two samples for serotype 6A, one sample for serotype 18C, and three samples for serotype 19A. The numbers in brackets are the numbers of pairwise comparisons
for the incomplete data sets.
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For sample 2, the serotype-speciﬁc IgG GMC for 8 of 12 serotypes (6 of 7 PCV7
serotypes) had waned signiﬁcantly (P  0.05) and was reﬂected by lower OIs for the
majority of serotypes, as measured by the three laboratories (Table S3).
One month after the PCV13 booster (sample 3), the serotype-speciﬁc IgG GMCs for
all PCV13 serotypes had increased signiﬁcantly (P  0.03), and the OIs reported by the
three laboratories were all positive (8) for PCV7 serotypes as well as serotypes 6A, 7F,
and 19A. The OIs were 8 for six samples, namely, ﬁve samples for serotype 1 and one
sample for serotype 3 from lab A. OIs were also 8 for four samples for serotype 1 and
two samples for serotype 5 from lab C and one sample for serotype 1 from lab B
(Table S4).
ICCs. Intraclass correlation coefﬁcients (ICCs) were used to examine agreement
across all three laboratories (Table 2). The ICCs ranged between 0.58 and 0.95 (median
ICC  0.83), indicating moderate-to-high agreement between laboratories. Again,
similar patterns of results emerged, with high ICC values for serotypes 18C, 6B, and 19F
and lower ICCs for serotypes 7F and 14.
Comparison of samples with positive (titer, 8) and negative (titer, 8) OPA results
between laboratories resulted in the following. All three laboratories recorded a
negative titer as 8. Kappa coefﬁcients were used to assess agreement in the classi-
ﬁcation of titers as positive or negative (Tables 3 to 5). We calculated overall kappa
coefﬁcients for all serotypes combined, as we were unable to compute serotype-
speciﬁc kappa coefﬁcients due to responses falling into too few categories. The
overall agreement was 92.8% for lab B and lab C, with a kappa coefﬁcient of 0.75.
This indicates good agreement between lab B and lab C in terms of positive or
negative classiﬁcation. Agreement was slightly lower for comparisons between lab
A and lab C (agreement  90.4%, kappa  0.73) and lower for comparisons
between lab A and lab B (agreement  83.3%, kappa  0.51).
DISCUSSION
This paper describes the results from three independent laboratories measuring
pneumococcal opsonophagocytic responses in pediatric sera following PCV7 immuni-
zation and in the same children before and after PCV13 immunization. For the results
from vaccination studies to be compared internationally, clinicians, laboratories, and
pharmaceutical companies must have conﬁdence that the assays provide reproducible
and meaningful results. Here we describe the results from three laboratories, Murdoch
Children’s Research Institute’s Pneumococcal Immunology Laboratory (MCRI; Australia),
the UCL Great Ormond Street Institute of Child Health (UCL; United Kingdom), and the
TABLE 3 Agreement in classiﬁcation of OIs by labs A and B as positive or negativea
Lab A OI
classiﬁcation
No. of samples with lab B OI classiﬁcation:
TotalNegative (OI < 8) Positive (OI > 8)
Negative (OI  8) 48 59 107
Positive (OI  8) 6 277 283
Total 54 336 390
aTwo-by-two contingency table and kappa statistics for all samples between lab A and lab B. Agreement 
83.3%; kappa  0.51.
TABLE 4 Agreement in classiﬁcation of OIs by labs A and C as positive or negativea
Lab A OI
classiﬁcation
No. of samples with lab C OI classiﬁcation:
TotalNegative (OI < 8) Positive (OI > 8)
Negative (OI  8) 68 28 96
Positive (OI  8) 8 270 278
Total 76 298 374
aTwo-by-two contingency table and kappa statistics for all samples between lab A and lab C. Agreement 
90.4%; kappa  0.73.
MOPA Comparison following Pneumococcal Immunization
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National Institute for Health and Welfare Vaccine Immunology Laboratory (Terveyden ja
Hyvinvoinnin Laitos [THL]; Finland), which were provided with 30 pediatric serum
samples and used their individual methods to measure the opsonophagocytic antibody
responses to the 13 serotypes in PCV13.
The pneumococcal opsonophagocytic assay (OPA) was ﬁrst introduced by Romero-
Steiner et al. in 1997 to measure the functional activities of antibodies in serum (6). In
2003, ﬁve laboratories performing OPAs took part in a multilaboratory evaluation (7).
Each laboratory was provided with the same protocol, seven target pneumococcal
strains (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F), two quality control sera, and 12
paired sera from adult donors who received one dose of 23vPPV. The report concluded
that the assay could be done in multiple laboratories with a high degree of accuracy.
Then in 2011, six laboratories (the original ﬁve plus one) assessed agreement using their
own optimized protocols (8). Five of six laboratories assayed 24 reference specimens,
and one laboratory assayed 19 unique samples. The sample proﬁle initially included
3 samples from patients preimmunized with 23vPPV and 21 samples from patients
postimmunized with 23vPPV, with three preimmunization samples removed from the
analysis, as the majority of the assayed values were at or less than the minimum
measurable titer. The ﬁnal number of samples included in the analysis was 16 samples
from healthy adults who had received 23vPPV. Five laboratories tested for at least 12
of the 13 serotypes in PCV13 (one laboratory failed to report titers for serotype 3),
and one laboratory tested for the 7 serotypes in PCV7. The precision, accuracy, and
concordance between the postimmunization samples included in the analysis demon-
strated an acceptable agreement.
Our study is the ﬁrst to perform an interlaboratory comparison using pediatric
samples. This is important since evaluation of PCV immunogenicity is critical following
immunization during infancy. The critical components of an OPA are the pneumococcal
strain used, the preparation and encapsulation of the serotype, the source of the
complement, heat inactivation of the sera, and the cultured phagocytes. The method
differences between the laboratories were minimal (Table 6). Each laboratory used
identical organisms from BEI Resources (with differences in the methods used for
culturing the strains and subtle differences in the MOPA groupings), the same source
for the baby rabbit complement, and the same phagocytic cells, with similar levels of
differentiation and passaging steps. Therefore, the differences in the results obtained
between the different laboratories are likely to be due to other factors, given the similar
protocols used.
In the present study, lab B and lab C reported high OIs to nonvaccine serotypes.
Song et al. (9) previously reported high OPA titers to serotype 7F in subjects who had
received only PCV7. They concluded that the high titer might not be vaccine induced
and may confer no protection in those individuals. Lin’s concordance coefﬁcient
and intraclass correlations were used to assess agreement and accuracy between the
laboratories, and kappa coefﬁcients were used to assess agreement in the classiﬁcation
of titers as positive or negative. Subgroup statistics to compare pre- and postimmuni-
zation samples were inappropriate, as each group comprised only 10 samples, and lab
C supplied OI results for fewer samples. However, examination of the supplementary
ﬁgures demonstrates a good relationship between all postimmunization (PCV13) sam-
TABLE 5 Agreement in classiﬁcation of OIs by labs B and C as positive or negativea
Lab C OI
classiﬁcation
No. of samples with lab B OI classiﬁcation:
TotalNegative (OI < 8) Positive (OI > 8)
Negative (OI  8) 50 26 76
Positive (OI  8) 1 297 298
Total 51 323 374
aTwo-by-two contingency table and kappa statistics for all samples between lab B and lab C. Agreement 
92.8%; kappa  0.75.
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ples and those serotypes in the vaccine. This is in agreement with the ﬁndings of
Juergens et al. (10), who reported a signiﬁcant correlation of serotype-speciﬁc IgG levels
and OPA results for infants postvaccination with PCV13. The agreement was not as
strong, especially for the non-PCV7 serotypes, in samples taken at 12 months after PCV7
vaccination and in samples taken preimmunization with PCV13 more than 4 years later
(sample 1 and sample 2). This may be due to the low-titer serotype-speciﬁc IgG. Lab B
and lab C detected functional responses to non-PCV7 serotypes, whereas lab A re-
ported negative titers in those samples. The majority of immunization trials report an
OI as8 (positive) or8 (negative), with no reference to the absolute serotype-speciﬁc
IgG concentration. As such, it is important that the laboratories performing an OPA are
consistent about measuring at this 8 or 8 interface. Song et al. also noted that the
functionality of anti-19F antibodies was at least 10-fold lower than the functionality
of antibodies to the other serotypes in PCV7. At that time, they suggested that the
cutoff of 8 may need to be altered for each serotype. New cutoff values for both
serotype-speciﬁc IgG and OPAs were published by Andrews et al. in 2014 (11), and
when these cutoff values were applied to the results from the current study, the
agreement between the three laboratories was even stronger. Our study demonstrates
different responses to individual serotypes, with the highest OIs reported to serotypes
6B and 9V and the lowest OIs to serotype 1, 3, and 4.
It has been shown that the polysaccharide-bound antibody isotypes of IgG2 and
IgG3, as well as IgM, can activate complement-mediated opsonization through the
classical pathway. Thus, the measurement of serotype-speciﬁc IgG and OPAs do not
always correlate. This is commonly seen in adult sera (9, 12), where nonspeciﬁc IgG with
low functional capacity, as well as IgM, may be present. However, in pediatric postim-
munization sera, the correlation is generally much stronger (10, 13, 14). Low levels of
nonspeciﬁc IgG with low functional capacity may explain the difference in OIs mea-
sured for non-PCV7 serotypes, described in the current study for those samples after a
microdose of 23vPPV and 4 years later (sample 1 and sample 2). Minor differences in
methods used by the three laboratories, including the ratios of pneumococci to HL-60
cells, the storage and viability of pneumococci, the speed of the rotating mixing
platform, the serotype panels used, and HL-60 differentiation protocols, may all affect
the ﬁnal result. This study was designed to compare the results from three independent
laboratories performing assays for measurement of functional responses to pneumo-
coccal immunization. There was no stipulation with regard to the method used, which
serotypes to include in the MOPA, the growth and number of the bacteria, the growth
and number of HL-60 cells, or the relative acceptance criteria (sensitivity and lower limit
of measurement and uncertainty). For our current study to have maximum impact, all
of these factors should be investigated further to ensure that we have conﬁdence in the
methods used in our laboratories.
A recent report from an international collaboration assigned OIs to the pneumo-
coccal reference serum of lot 007sp and an FDA OPA calibration serum, which means
that, for the ﬁrst time, laboratories conducting opsonophagocytosis assays now have a
designated standard to run in each of their assays (15). This will help to improve the
accuracy and standardization of these assays in future studies. Furthermore, the
introduction of an annual quality assurance program would be a most worthwhile
exercise for all laboratories performing these assays to ensure that immunogenicity
results from ongoing vaccine studies are reported with conﬁdence.
Conclusions. This is the ﬁrst report of an interlaboratory comparison of op-
sonophagocytic responses in pediatric samples. The level of agreement between the
MCRI, UCL, and THL laboratories depended on the timing of the sample collection and
was good for vaccine serotypes, while agreement was lower for nonvaccine serotypes.
Overall, this study demonstrates good agreement in OPA measurement in pediatric
samples across three laboratories, and despite minor differences in protocol, the OI
results from each laboratory may be compared with conﬁdence.
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MATERIALS AND METHODS
Participating laboratories. The Murdoch Children’s Research Institute Pneumococcal Immunology
Laboratory (MCRI), the WHO Pneumococcal Serology Reference Laboratory, UCL Great Ormond Street
Institute of Child Health, United Kingdom (UCL) and the National Institute for Health and Welfare Vaccine
Immunology Laboratory, Helsinki, Finland (THL). The laboratories have been randomly deidentiﬁed, and
results are reported as from lab A, lab B, and lab C.
Samples. Thirty sera from a sample collection stored at the MCRI were separated into three equal
aliquots and were sent on dry ice to the WHO Pneumococcal Serology Reference Laboratory, UCL
Institute of Child Health, United Kingdom (UCL), and the National Institute for Health and Welfare,
Helsinki, Finland (THL). The samples were from 10 children who were part of the Fiji Pneumococcal
Project and the Fiji follow-up study. Full details of these studies have been published previously (16, 17).
Ethics approval was obtained from the Fiji National Research Ethics Review Committee (FNRERC) and the
Royal Children’s Hospital Human Research Ethics Committee (Melbourne, Australia). Three samples
previously collected from each study participant were used.
Five children received 3 doses of Prevnar (PCV7) at 6, 10, and 14 weeks, and 5 children received 2
doses of PCV7 at 6 and 14 weeks. At 18 months of age, all 10 children received a 20% dose of 23-valent
Pneumovax (23vPPV). Sample 1 was collected at 4 weeks after 23vPPV administration, at 18 months of
age. As part of the Fiji study, the guardians of these children were contacted to permit the children to
be part of a follow-up study when their ages were between 4.9 and 7.4 years, and the children received
a further dose of the 13-valent pneumococcal conjugate vaccine (PCV13). Sample 2 was taken prior to
the PCV13 booster, and sample 3 was taken 1 month after the immunization (Table 7).
Participating laboratories were asked to include the sera in their routine assays and perform
opsonophagocytosis assays (OPAs) on the serum samples using their own method for all 13 serotypes
in PCV13 (1, 3, 4, 5, 6 A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). The laboratories were blind to the
vaccination status of the samples. Results were collated and analyzed at the MCRI.
Strains. The following reagents were obtained through the NIH Biodefense and Emerging Infections
Research Resources Repository, NIAID, NIH: Streptococcus pneumoniae strain SPEC1, BEI Resources
accession no. NR-13388; strain OREP3, NR-13389; strain OREP4, NR-13390; strain STREP5, NR-13391; strain
TREP6A, NR-13392; strain SPEC6B, NR-13393; strain OREP7F, NR-13394; strain EMC9V, NR-13395; strain
STREP14, NR-13396; strain OREP18C, NR-13397; strain TREP19A, NR-13398; strain SPEC19F, NR-13399; and
strain EMC23F, NR-13400.
Serotype-speciﬁc IgG. Serotype-speciﬁc IgG was measured in the Pneumococcal Immunology
Laboratory at the MCRI using a previously described modiﬁcation of the gold standard WHO enzyme-
linked immunosorbent assay (18).
OPAs. Each laboratory’s method is based on the multiplex opsonophagocytic assays (MOPAs) and
OPAs developed at the University of Alabama, Birmingham, AL (5). Minor method differences between
the three laboratories are summarized in Table 6. In general, sera were heat inactivated at 56°C for 30 min
prior to serial dilutions in a 96-well sterile microtiter plate containing Hanks’ balanced salt solution with
Mg2, Ca2, and gelatine (opsono buffer [OB]). Frozen stocks of pneumococci were thawed and washed
with OB and diluted to 5 104 CFU/serotype/ml. Standard bacterial dilutions were added to all wells, and
the plate was incubated at room temperature for 30 min. At 30 min, 10 l of baby rabbit complement,
thawed just prior to use, was added, followed by addition of 40 l of HL-60 cells (2  107 cells/ml) to all
test wells. A bacterial control (heat-inactivated fetal calf serum [FCS] in place of human serum and no
complement) and a complement control (no serum) were included on all plates. Plates were placed on
a horizontal shaker and incubated for 45 min at 37°C in 5% CO2. The reaction was stopped at 45 min by
placing the plate on ice. A 10-l aliquot of this mixture was then spotted onto Todd-Hewitt broth–yeast
extract (THYE; 0.5%) agar plates. After application of an overlay of THYE agar containing selective
antibiotics (optochin, spectinomycin, streptomycin, or trimethoprim) and 2,3,5-triphenyltetrazolium
chloride (TTC), the plates were incubated overnight at 37°C in 5% CO2.
TTC is recommended for the detection of microbial growth by means of TTC reduction and aids in
the counting of colonies using an automatic colony counter. After overnight incubation, colonies on the
plates were counted, and the results were expressed as opsonization indices (OIs), where the OI is
deﬁned as the interpolated dilution of serum that kills 50% of bacteria. OIs were determined using either
an in-house (THL) software or Opsotiter 3 (license granted to Licensee by UABRF) (19).
Statistics. Serotype-speciﬁc IgG concentrations and OIs were reported using geometric means and
95% conﬁdence intervals. Summary statistics are presented separately by serotype and laboratory. The
OIs were classiﬁed as being positive or negative based on the current recommended cutoff value of 8
TABLE 7 Timing of immunization and blood collection
No. of
samples
(n  10)
Doses and timing of
PCV7 vaccination
Sample 1 patient
Median age (yr) (range)
of patient providing
sample 2 before
PCV13 vaccination
Median no. of days (range)
after PCV13 vaccination for
patient providing sample 3
Median age (yr)
(range)
Median no. of days
(range) after a 20%
23vPPV vaccination
5 2 doses at 6 and 14 wk 1.47 (1.44–1.51) 30 (28–49) 6.50 (5.60–7.39) 28 (28–28)
5 3 doses at 6, 10, and 14 wk 1.44 (1.43–1.50) 29 (27–35) 5.46 (4.93–7.34) 28 (28–31)
All 2 or 3 doses 1.46 (1.43–1.51) 29 (27–49) 6.03 (4.93–7.39) 28 (28–31)
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(negative) and 8 (positive). All negative titers were assigned a value of 4 and included in all statistical
analyses.
Lin’s concordance correlation coefﬁcients (20) were used to examine agreement in OIs between each
pair of laboratories (i.e., lab A versus lab B, lab A versus lab C, and lab B versus lab C). Lin’s concordance
coefﬁcient is a combined measure of accuracy (how well the data follow the 45° line of perfect
agreement on a square scatterplot) and precision (how tightly the points cluster around the line). A value
of 0 indicates no concordance, while a value of 1 indicates perfect concordance.
Intraclass correlation coefﬁcients (ICCs) were used to assess agreement among the OIs across the
three laboratories. The ICC values were estimated using a mixed-effects analysis of variance (ANOVA)
model with a ﬁxed effect for laboratory and a random effect for sample. The ICC is a ratio of the variance
among samples to the total variance. ICC values can range between 0 and 1, with higher values
representing higher correlations between measurements of the same sample.
To examine agreement in classiﬁcation between the laboratories, we displayed the data using 2 by
2 contingency tables and calculated kappa coefﬁcients, a chance-corrected measure of agreement
between two categorical variables. A kappa coefﬁcient of 0 indicates no agreement, while a value of 1
indicates perfect agreement (21). Landis and Koch (21) classiﬁcation of the kappa coefﬁcients states that
0.00 to 0.20 indicates slight agreement, 0.21 to 0.40 indicates fair agreement, 0.41 to 0.60 indicates
moderate agreement, 0.61 to 0.80 indicates substantial agreement, and 0.81 to 1.00 indicates almost
perfect agreement.
Due to nonnormality, OIs were log transformed, using a base 10 logarithmic transformation, prior to
calculations of Lin’s concordance coefﬁcients and ICCs. All coefﬁcients of agreement were calculated
using Stata version 14.1, while ﬁgures were produced in Stata and GraphPad Prism. A P of 0.05 was
considered statistically signiﬁcant in all cases, unless stated otherwise.
Subgroup analyses. Post hoc analysis of geometric means and 95% conﬁdence intervals for
serotype-speciﬁc IgG and OIs were calculated for each blood collection time point to investigate
differences between laboratories.
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